(ATEC) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It details various institutional trading strategies, including position trading, momentum breakout, and risk hedging, based on AI-generated signals. The analysis also includes multi-timeframe signal strengths and key support/resistance levels for ATEC.
Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses
Alphatec Holdings (ATEC) saw its stock rise 5.9% after reporting narrowed Q2 net losses and reaffirming its 2026 revenue guidance of approximately US$882 million. The company also filed a shelf registration for 800,000 common shares. This performance highlights Alphatec's cost discipline and continued investment in growth initiatives, reinforcing its path towards potential sustained profitability despite ongoing competition.
Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses
Alphatec Holdings (ATEC) saw its stock rise by 5.9% after announcing Q2 results that showed a narrowed net loss and reaffirmed its 2026 revenue guidance of approximately US$882 million. The company also filed an US$8.12 million shelf registration related to an ESOP offering. This positive movement is attributed to management's continued focus on cost discipline and growth initiatives, reinforcing the company's investment narrative of achieving sustained profitability through its spine portfolio and EOS ecosystem.
HC Wainwright Analysts Raise Earnings Estimates for Alphatec
HC Wainwright analysts have raised their Q3 2026 EPS estimate for Alphatec (NASDAQ:ATEC) to a loss of $0.02 from $0.06, maintaining a "Buy" rating and a $24 price target. The firm anticipates Alphatec will achieve positive quarterly earnings in 2027, projecting EPS between $0.08 and $0.18, and further growth to $0.79 in 2028 and $1.05 in 2029. Despite a recent strong revenue report, the company remains unprofitable overall, with a consensus "Moderate Buy" rating from analysts and an average price target of $17.40.
ATEC Stock Price and Chart — NASDAQ:ATEC
This article provides a detailed overview of Alphatec Holdings, Inc. (NASDAQ:ATEC) stock, including its current price, historical performance, key financial metrics, and analyst ratings. It highlights the company's focus on spinal fusion technology and reports its Q2 2026 earnings, showing revenue growth and increased adjusted EBITDA. The article also includes various trading ideas and technical analyses for ATEC.
HC Wainwright Cuts Earnings Estimates for Alphatec
HC Wainwright has reduced its FY2027 earnings per share (EPS) estimate for Alphatec to $0.47 from $0.59, while reiterating a "Buy" rating and a $24 price target. This revision follows Alphatec's recent quarterly earnings which met EPS expectations of $0.07 and surpassed revenue forecasts with $213.51 million, marking a 15.1% year-over-year increase. Despite the lowered earnings forecast, analyst sentiment remains largely positive for the medical technology company.
Enterprise value to EBITDA forward of Alphatec Holdings, Inc. – DUS:L1Z1
This page from TradingView provides financial information for Alphatec Holdings, Inc. (L1Z1) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBITDA forward metric. The content highlights financial data sourced from ICE Data Services, FactSet, and SEC filings from Quartr.
What Alphatec Holdings (ATEC)'s Reaffirmed 2026 Outlook and Narrowing Losses Mean For Shareholders
Alphatec Holdings (ATEC) recently reported Q2 and H1 2026 results, showing reduced net losses and reaffirming its full-year 2026 revenue guidance of approximately US$882 million. This positive outlook, driven by increasing surgeon adoption and procedural volumes, supports the company's path toward profitability despite ongoing operating losses. The reaffirmed guidance and narrowing losses are seen as a positive development for investors, though risks associated with cash burn and cost pressures remain.
Alphatec Holdings general counsel sells $78,821 in ATEC shares
Tyson Eliot Marshall, General Counsel of Alphatec Holdings (NASDAQ:ATEC), sold 8,168 shares for a total of $78,821 to cover tax withholding obligations from vested restricted stock units. This sale was conducted under a Rule 10b5-1 trading plan. Despite the stock being down 56% year-to-date, analysts predict a return to profitability for Alphatec Holdings this year, and the company recently reported increased Q2 revenue and adjusted EBITDA.
Insider Selling: Alphatec (NASDAQ:ATEC) General Counsel Sells 8,168 Shares
Alphatec (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 8,168 shares of the company's stock, valued at $78,821.20, on August 5th. This transaction was part of a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations from vested equity awards. Despite this insider sale, Alphatec holds a "Moderate Buy" consensus rating from analysts with an average price target of $17.40, significantly higher than its current trading price of $9.31.
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
This article discusses Alphatec Holdings' second-quarter earnings report and how analysts have reacted, including changes to their future earnings forecasts. It highlights the company's revenue and earnings per share, and provides an updated consensus view on the stock's future performance.
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Alphatec Holdings recently reported its second-quarter earnings, leading to analysts updating their price targets and earnings forecasts for the company. While sales beat expectations, earnings per share missed targets, resulting in a slight reduction in the consensus price target. The article examines the sentiment of analysts following these results and updates on Alphatec's financial performance and future outlook.
What Alphatec Holdings (ATEC)'s Reaffirmed 2026 Outlook and Narrowing Losses Mean For Shareholders
Alphatec Holdings (ATEC) has reported its Q2 and H1 2026 results, showing reduced net losses and reaffirming its full-year 2026 revenue guidance of approximately US$882 million. This positive outlook, driven by increasing surgeon adoption and procedural volumes, supports the company's investment narrative toward profitability despite ongoing losses and competitive pressures. Investors should consider how these improvements impact previous analyst expectations and the company's valuation.
ETFs Investing in Alphatec Holdings, Inc. Stocks
This article lists various ETFs that invest in Alphatec Holdings, Inc. (ATEC) stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, and performance metrics for each fund. The funds primarily target small-cap and healthcare sectors, indicating ATEC's presence within these investment strategies. The data helps potential investors identify ETFs that hold ATEC stocks, offering diversified investment opportunities.
Narrower Losses And Reaffirmed 2026 Revenue Guidance Might Change The Case For Investing In Alphatec Holdings (ATEC)
Alphatec Holdings (ATEC) reported narrower net losses in Q2 2026 and reaffirmed its full-year 2026 revenue guidance of approximately US$882 million. This consistent outlook, along with reduced losses, reinforces management's confidence in growth and surgical volume, but the company still faces risks related to ongoing high investment and competitive intensity affecting profitability. The article suggests these updates might shift the investment narrative and risk profile for ATEC, with some analysts potentially revising their more conservative forecasts.
Alphatec Holdings, Inc. $ATEC Shares Purchased by Renaissance Technologies LLC
Renaissance Technologies LLC significantly increased its stake in Alphatec Holdings, Inc. ($ATEC) by 21.3% in the first quarter of 2026, acquiring an additional 184,969 shares and bringing its total holdings to over 1 million shares. Other institutional investors also boosted their positions in the medical technology company. Analysts generally maintain a "Moderate Buy" rating for Alphatec with a consensus price target of $17.13, despite one firm lowering its target.
Alphatec Holdings (ATEC) Stock Sinks As Margin Gains Fail To Convince
Alphatec Holdings' stock (ATEC) dropped 7.5% despite reporting improved Q2 2026 results, including narrowed losses, increased revenue, and higher adjusted EBITDA with a 17% margin. While the company showed strong surgeon adoption and operating leverage, investors remain concerned about execution risks with new products and ongoing legal investigations, which are preventing them from seeing the improved financials as a permanent fix.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alphatec Holdings (ATEC), Amgen (AMGN) and Vertex Pharmaceuticals (VRTX)
The article provides an overview of recent analyst ratings for three healthcare stocks: Alphatec Holdings (ATEC), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX). Alphatec Holdings received a Strong Buy consensus with significant upside potential. Amgen has a Moderate Buy consensus but with a slight downside from current levels, while Vertex Pharmaceuticals also has a Strong Buy consensus indicating substantial upside.
Alphatec Holdings Number of Employees 2026 | Employee Count & Headcount Data
Alphatec Holdings (NASDAQ: ATEC) has approximately 952 employees worldwide as of March 2026, representing a 14.2% growth since 2023. The company is actively hiring, with 68 active job postings in 2026, and its workforce is primarily concentrated in North America, with Finance and Operations being the largest functional group. The average salary at Alphatec Holdings is $109,339, though employee sentiment is currently negative and declining.
(ATEC) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), highlighting a strong near-to-mid-term sentiment but a weak long-term outlook. It identifies an exceptional 185.0:1 risk-reward setup targeting a 43.3% gain against a 0.2% risk and outlines specific position, momentum, and risk-hedging trading strategies for different risk profiles. The analysis emphasizes the prevailing positive sentiment and offers multi-timeframe signal analysis with support and resistance levels.
Alphatec Holdings, Inc. SEC Filing (Aug 5, 2026)
Alphatec Holdings, Inc. (ATEC) filed a Form 144 with the SEC on August 5, 2026, indicating a proposed sale of securities. The filing details the sale of 8,168 common shares with an aggregate market value of $84,538.80, acquired on the same date as Restricted Stock Units from the issuer. This notice is a standard disclosure for individuals intending to sell restricted or controlled securities.
UBS Adjusts Price Target on Alphatec Holdings to $16 From $15, Maintains Buy Rating
UBS has increased its price target for Alphatec Holdings (ATEC) to $16 from $15, while reaffirming a Buy rating on the stock. This adjustment reflects the analyst's updated outlook for the medical device company. Alphatec Holdings specializes in technology for spinal disorder treatment and has recently been the subject of several analyst recommendations.
Alphatec Holdings, Inc. Stock 12‑Month Price Target Raised to $16.07, Implies 55% Upside
Analysts have raised the 12-month price target for Alphatec Holdings, Inc. stock to $16.07, up from $15.86, with forecasts ranging from $12 to $24 per share. This new target suggests a potential upside of approximately 55% based on the August 4 closing price. The consensus rating for Alphatec Holdings, Inc. remains a "Buy" among all 14 covering analysts.
Alphatec earnings up next: Can spine disruptor ease growth fears?
Alphatec Holdings Inc. is scheduled to report second-quarter earnings, with investors closely watching whether the company's "proceduralization" strategy can sustain market-share gains amidst concerns about surgical revenue growth. Analysts expect 7 cents per share on revenue of $211.24 million, and while all 14 analysts rate the stock a buy, there are investor worries about potential guidance cuts and the ability of margin expansion to offset growth moderation. The report will be crucial in determining if recent downgrades are prescient or if the stock's significant decline presents an oversold opportunity.
Alphatec Q2 2026 Earnings Call Transcript
Alphatec reported strong Q2 2026 results, with revenue up 15% to $214 million and adjusted EBITDA up 53% to $36 million, driven by increased surgical adoption and procedural volume. The company generated positive free cash flow and raised its full-year adjusted EBITDA guidance to $140 million while maintaining revenue guidance of $882 million. Management emphasized the success of their procedural-based approach, the strategic value of EOS and EOS Insight in driving surgeon engagement, and their continued focus on clinical distinction and market expansion.
ATEC Q2 2026 slides: profitability growth outpaces revenue gains
Alphatec Holdings Inc. (ATEC) reported strong Q2 2026 financial results, with adjusted EBITDA surging 53% to $36 million on 15% revenue growth to $214 million, significantly outpacing Wall Street expectations for revenue. Despite strong operational performance and increased profitability, the stock declined 2.96% after hours due to investor concerns about a 2.7% decline in revenue per case and flat EOS imaging revenue. The company affirmed its full-year 2026 revenue guidance of $882 million while raising adjusted EBITDA expectations to $140 million, highlighting its focus on clinical distinction and an integrated procedural ecosystem.
Alphatec Holdings (NASDAQ:ATEC) Shares Dip Slightly After In-Line Q2 Results
Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $213.5 million and non-GAAP EPS of $0.07, aligning with analyst estimates. Despite in-line results and a 15% year-over-year revenue increase, shares experienced a slight dip after hours, likely due to full-year revenue guidance remaining below consensus. The company reaffirmed its full-year revenue outlook and raised its adjusted EBITDA guidance.
Alphatec Holdings (Nasdaq: ATEC) lifts 2026 EBITDA outlook after Q2
Alphatec Holdings (ATEC) reported strong Q2 2026 results, with total revenue up 15% year-over-year to $214 million and adjusted EBITDA reaching $36 million. The company reaffirmed its full-year 2026 revenue guidance of $882 million and raised its adjusted EBITDA outlook from $134 million to $140 million, while maintaining a target of at least $20 million in free cash flow. Despite continued GAAP net losses, Alphatec highlights significant growth in surgical revenue, margin expansion, and surgeon adoption, attributing success to its "Organic Innovation Machine" and focus on clinical distinction.
Alphatec earnings up next: Can spine disruptor ease growth fears? By Investing.com
Alphatec Holdings Inc. is set to report second-quarter earnings, with analysts keenly watching if its growth momentum can alleviate investor concerns about its surgical revenue trajectory. Despite all 14 analysts rating the stock a buy with a 56% implied upside, EPS estimates have slightly declined, signaling caution. Key areas of focus include the "proceduralization" strategy's ability to sustain market share gains, execution in the EOS imaging business, and whether margin expansion can offset any potential moderation in volume growth.
Earnings Flash (ATEC) Alphatec Holdings, Inc. Reports Q2 Revenue $213.5M, vs. FactSet Est of $211.3M
Alphatec Holdings, Inc. (ATEC) announced its Q2 revenue reached $213.5 million, surpassing the FactSet estimate of $211.3 million. The company reaffirmed its earnings guidance for the full-year 2026. This positive financial update follows several recent analyst initiations and price target adjustments for Alphatec Holdings.
Enterprise value to revenue forward of Alphatec Holdings, Inc. – NASDAQ:ATEC
This article focuses solely on the enterprise value to revenue forward for Alphatec Holdings, Inc. (NASDAQ: ATEC). The content appears to be a financial data point from TradingView, indicating a specific period's value, change, and percentage change for this metric. No additional financial analysis or details are provided beyond this isolated data point.
Alphatec Holdings, Inc. Revenue Breakdown – NASDAQ:ATEC
Alphatec Holdings, Inc. (NASDAQ: ATEC) generated $764.15 million in revenue last year, primarily from its Spinal Surgery Implants segment. This segment was also its top performer the previous year, contributing $611.56 million. The United States was the largest geographical contributor, accounting for $716.14 million of the revenue.
UBS Initiates Alphatec Holdings at Buy With $15 Price Target
UBS has initiated coverage on Alphatec Holdings (ATEC) with a Buy rating and a $15 price target. This initiation suggests a positive outlook from UBS on the company's future performance.
Alphatec Holdings, Inc. Revenue Breakdown – SWB:L1Z1
Alphatec Holdings, Inc. (SWB:L1Z1) generated €650.62 million in revenue last year, primarily from its Spinal Surgery Implants segment. The United States was the largest contributor to its revenue, accounting for €609.74 million. This represents an increase from the previous year's figures for both the segment and the region.
UBS Initiates Alphatec Holdings at Buy With $15 Price Target
UBS has initiated coverage on Alphatec Holdings (NASDAQ: ATEC) with a "Buy" rating and a price target of $15. This follows similar initiations from Stephens and BMO Capital with "Overweight" and "Outperform" ratings, respectively. The medical device company, focused on spinal disorder treatment, has seen several analyst actions recently, including Needham adjusting its price target to $14 while maintaining a "Buy" rating.
Alphatec Holdings Inc (ATEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Alphatec Holdings Inc (ATEC), detailing its price momentum, support and resistance levels, and the readings from various technical indicators and moving averages. As of the analysis, ATEC's price momentum score is 4.02 and the stock is trading between a resistance level of 9.74 and a support level of 7.81. While technical indicators show mixed signals, moving averages suggest a generally positive outlook.
Alphatec Holdings Inc (ATEC) Risk Assessment: Volatility, Financial Risk & Investment Risk
Alphatec Holdings Inc (ATEC) has a current risk assessment score of 6.27, placing it 59th out of 199 in the Healthcare Equipment & Supplies industry. The stock's beta of 0.90 suggests it is less volatile than the S&P 500. The article details various risk metrics including VaR, maximum drawdown, volatility, Sharpe Ratio, and liquidity indicators.
ATEC|Alphatec Holdings Inc|Price:8.670|Chg%:+0.410
This article provides a comprehensive stock analysis of Alphatec Holdings Inc (ATEC) by TradingKey. It highlights the company's relatively stable fundamentals, high growth potential (averaging 58.45% revenue growth over 3 years), and fair valuation within the Healthcare Equipment & Supplies industry. Despite recent weak market performance, Alphatec Holdings exhibits strong fundamentals and significant institutional ownership, with analysts rating it as a "Buy" and a target price of 16.46.
Alphatec Holdings, Inc. Revenue Breakdown – DUS:L1Z1
This article provides a revenue breakdown for Alphatec Holdings, Inc. (DUS:L1Z1). Last year, the company generated 650.62 million EUR, with its top-performing segment, Spinal Surgery Implants, contributing the entire amount. The United States was the greatest regional contributor, accounting for 609.74 million EUR of the revenue.
Enterprise value to revenue forward of Alphatec Holdings, Inc. – MUN:L1Z1
This article focuses on the enterprise value to revenue forward metric for Alphatec Holdings, Inc. (MUN:L1Z1). It appears to be a financial data point presented on a trading platform, indicating the company's valuation in relation to its future revenue. The content mainly consists of navigation and platform-related information, with the core financial data point itself not elaborated upon.
Alphatec Holdings Inc|Price:8.200|Chg%:+0.140
Alphatec Holdings Inc (ATEC) is a medical device company specializing in technology for surgical treatment of spine disorders. The company's innovative approaches include the Alpha InformatiX (AIX) Platform, integrating systems like EOS imaging and an alignment mobile application. Key executives and major shareholders are listed, with Mr. Patrick S. Miles serving as Chairman, President, and CEO, holding 4.92 million shares.
Alphatec (ATEC) Wells Fargo 20th Annual Healthcare Conference 2025 Summary
Alphatec (ATEC) presented a summary of its financial performance, market strategy, and product development at the Wells Fargo 20th Annual Healthcare Conference 2025. The company highlighted sustained revenue growth, expanded profitability, and projections for positive free cash flow. Key initiatives include surgeon engagement, sales force expansion, and the upcoming launch of the Valence robot and enhancements to EOS Insight and PTP Corpectomy for spine surgery.
ATEC|Alphatec Holdings Inc|Price:8.200|Chg%:+0.140
Alphatec Holdings Inc (ATEC) shows stable fundamentals and high growth potential, though its stock price is expected to trend down in the medium term despite strong fundamentals. The company is considered fairly valued in the Healthcare Equipment & Supplies industry. Analysts currently rate ATEC as a "Buy" with a target price of $16.58, indicating significant upside potential.
Alphatec (ATEC) Barclays 28th Annual Global Healthcare Conference Summary
Alphatec (ATEC) presented a summary of its performance and strategy at the Barclays 28th Annual Global Healthcare Conference. The company emphasized strong growth, profitability, and market share gains driven by clinical distinction and procedural solutions. Key growth drivers include surgeon adoption, increasing utilization, and enabling technologies like the Valence robot, which supports minimally invasive spine surgeries.
Stephens Initiates Alphatec Holdings at Overweight With $15 Price Target
Stephens has initiated coverage on Alphatec Holdings (ATEC) with an "Overweight" rating and a $15 price target. This follows BMO Capital's earlier "Outperform" initiation with an $11 price target in July. The medical device company focuses on technology for surgical treatment of spine disorders.
Stephens initiates Alphatec stock with Overweight on spine surgery strategy By Investing.com
Stephens initiated coverage on Alphatec Holdings (NASDAQ:ATEC) with an Overweight rating and a $15.00 price target, viewing the company as a disruptor in spine surgery through its proceduralization strategy. Despite recent stock underperformance due to concerns about surgical growth durability and EOS execution, Stephens believes Alphatec has significant runway for market share gains and that the current pullback represents an attractive entry point. InvestingPro analysis also suggests the stock is undervalued, with analysts revising earnings upwards and expecting profitability this year.
Alphatec Holdings, Inc. (ATEC): Investor Outlook Highlights Nearly 93% Upside Potential
Alphatec Holdings, Inc. (ATEC), a medical device company focused on spinal disorders, shows significant growth potential with an average analyst target price suggesting a 93.47% upside. Despite current unprofitability with a negative EPS of -0.80, the company boasts strong revenue growth of 13.60% and a substantial free cash flow of $54.57 million. Analysts are unanimously bullish with 12 buy ratings, underscoring confidence in Alphatec's innovative products and market expansion strategies.
ATEC6342884 Bond Coupon Profile — Rate & Payments
This article provides a bond coupon profile for Alphatec Holdings, Inc. bond ATEC6342884, detailing its interest rate and payment schedule. The bond has a current coupon rate of 0.75%, with the next payment scheduled for September 15, 2026. The profile offers an in-depth breakdown of the bond's coupon, redemption, and risks, highlighting upcoming and past payment dates.
ATEC6342884 Bond Risk Profile
This article provides a risk profile for the ATEC6342884 bond, specifically Alphatec Holdings, Inc. 0.75% 15-MAR-2030, accessible through TradingView. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability. The platform also offers access to exclusive analyst ratings for bonds.
ATEC6342884 Bond Profile — Key Metrics
This article provides key metrics for the ATEC6342884 bond profile, issued by Alphatec Holdings, Inc. The bond is a 0.75% bond maturing on March 15, 2030, with an outstanding amount of 405 million USD. Alphatec Holdings specializes in spinal fusion technology products and solutions.
